Filter posts

Positive Phase 2 results for TOPICA’s luliconazole

TOPICA Pharmaceuticals had positive results from its Phase 2 clinical study evaluating luliconazole, a topical …

Long-term immune response for Vical's TransVax™ vaccine in Phase 2 trial

Vical Incorporated (Nasdaq:VICL) announced that TransVax™ cytomegalovirus vaccine continued to demonstrate an overall increase in …

Inovio reports clinical trial progress of cervical cancer vaccine

Inovio Biomedical Corporation (NYSE Amex: INO) announced safety and immunogenicity data from its therapeutic cervical …

Immunovaccine begins trading as “IMV”

Immunovaccine Inc. (TSX-V:IMV) will begin trading on the TSX-Venture Exchange as a Tier 1 issuer …

Oncolytics enters into agreement with FDA for Phase 3 trial of REOLYSIN®

Oncolytics Biotech Inc. (“Oncolytics”) (TSX:ONC, NASDAQ:ONCY) has reached an agreement with the FDA under the …

WILEX receives approval for Phase I trial

WILEX AG (ISIN DE0006614720 / Frankfurt Stock Exchange / Prime Standard) announced that the German …

Medicago begins human testing of flu vaccine

Medicago Inc. (TSX-V: MDG) announced a Phase I trial for its H5N1 Avian Influenza vaccine. …

Provectus starts Phase 1 trial for liver cancer treatment

Provectus Pharmaceuticals, Inc. (OTCBB: PVCT) has initiated a Phase 1 study of PV-10 for liver …

XOMA to initiate Phase 2 program for Type 2 Diabetes and Cardiovascular Disease

XOMA Ltd. (Nasdaq:XOMA) announced plans for the Phase 2 clinical development of its anti-inflammatory drug …

U.S. Navy to fund Vical's H1N1 vaccine

The U.S. Navy has awarded a contract for $1.25 million to Vical Incorporated (Nasdaq:VICL) for …